Co-founder at Simbiz, VP HR & Operations at Yonalink Ltd., HRBP at Chemomab Therapeutics Ltd.
Exciting news from Chemomab!
Our heads of R&D Ilan Vaknin and Revital Aricha preparing to discuss the fine points of one of our translational study posters at EASL 2024. For more information see https://lnkd.in/eVtPGd4g
Dear Connections, A gentle reminder to register for the upcoming webinar on 'Moving compounds to IND using predictive retina models'. I will be chairing the session with an amazing panel of speakers from Charles River Laboratories and Newcells Biotech Ltd who will give their perspective on regulatory, technology, and scientific advancements. They will also delve into strategies for streamlining the clinical development pipeline, with a special focus on retina-related compounds Please register at the below link: #Newcells #VisionResearch #Retina
🌐 Upcoming Webinar: Moving compounds to IND using predictive retina models 🌐 📅 June 19th ⏰ 2:00 PM BST 🔬Featuring: Dr Lauren E. Black - Distinguished Scientist/Consultant, working mainly at the first in human (FIH) stage - in high-risk diseases using novel products at Charles River Laboratories Dr Roxana Redis - Associate Science Director, leading the development of the ASO hit to lead platform within Early Discovery at Charles River Laboratories Dr Valeria Chichagova, PhD - Director of Technology Our expert panelists will share their insights from Regulatory, Technology, and Scientific Perspectives. They will also delve into strategies for streamlining the clinical development pipeline, with a special focus on retina-related compounds. 🔗 Secure your spot now. Find out more and register here: https://lnkd.in/eEZqXdEj #Newcells #VisionResearch #Retina #PredictiveModels
Happy #GlobalBiosimilarsWeek! Check out Biologics & Biosimilars Collective Intelligence Consortium (BBCIC)'s timeline for useful insights and information about the world of #biosimilars.
As we celebrate #GlobalBiosimilarWeek 2024, hear from AMCP's Chief Science Officer & Executive Director of BBCIC, Cate Lockhart, PharmD, PhD about what AMCP is doing to participate in the development of #biosimilars across the world. Learn more: https://bit.ly/48F8pkg
Join Dr. Ernest Heimsath as he discusses his latest scientific poster in collaboration with #CellSignalingTechnology. This presentation demonstrates how a multiscale high throughput approach enables a comprehensive evaluation of TGF-β/SMAD pathway activation. See the full poster presentation here: https://bit.ly/3xvETio #Cancerresearch
Here it is - out just in time for the holidays! 🎄 We are pleased (and somewhat relieved) to finally announce the publication of our seminal review on the octadecanoids. For those of you not familiar with octadecanoids, they are the little studied C18-carbon cousins of the more well-known #eicosanoids. These lipid mediators exert potent functions in multiple biological processes. Within these 90 pages, you will find our best attempt to summarize as much of the octadecanoid literature as possible. We provide a detailed review of the field, including nomenclature, formation and biological activity of these important #lipid mediators. We hope that this work will help spur interest in our favorite molecules! Amazing effort led by Johanna Revol-Cavalier and Alessandro Quaranta with John Newman, Alan Brash and Mats Hamberg. Here is a link to the paper - which is freely available open access 👇 https://lnkd.in/dKxz9VpA Grateful for the support from Karolinska Institutet, Hjärt-Lungfonden, Vetenskapsrådet / Swedish Research Council as well as Larodan AB.
Join the National Science Foundation (NSF) tomorrow, July 12 at 10:30 a.m. PT for an information session on a new NSF funding opportunity called Privacy-preserving Data Sharing in Practice (PDaSP). The PDaSP program will support use-inspired and translational research projects focused on developing and deploying practical solutions that enable sharing and/or using data in a privacy-preserving manner. https://lnkd.in/gzZNCy85
Scientific Review Officer at NIH/CSR; former Professor at Columbia University Irving Medical Center
Excited to share that our study on the cell origin of IPMN is now published! This work would not have been possible without the dedications of my postdoc, Dr. Kiyoshi Saeki, and my collaborator, Dr. Janel Kopp. In our studies, we found that Acvr1b loss, likely through abrogation of Activin signaling, is one of the few pathways identified to date that promotes precancerous lesion formation from both acinar and ductal cells expressing Kras G12D. https://lnkd.in/ei6HcgF5
Join Dr. Ernest Heimsath as he discusses his latest scientific poster in collaboration with #CellSignalingTechnology. This presentation demonstrates how a multiscale high throughput approach enables a comprehensive evaluation of TGF-β/SMAD pathway activation. See the full poster presentation here: https://bit.ly/3xvETio #Cancerresearch
🎉 EMA Approves RHEACELL’s Phase 3 CVU Trial! We’re excited to announce EMA approval for our allo-APZ2-CVU Phase 3 trial in chronic venous ulcers (CVU). This multi-center, double-blinded study will evaluate our ABCB5+ stem cell therapy in 250 patients across 100+ sites. A pivotal step toward innovative treatments for patients with unmet needs! #EMAApproval #Phase3 #StemCellTherapy #ChronicVenousUlcers #RHEACELL
We are happy to announce key milestones in our ongoing clinical program: RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers You will always find our press releases, interesting literature and the newest scientific papers and on our website using the following link: https://lnkd.in/ggCNBKx4
We look forward to hosting a scientific symposium at the EB Clinet Conference 2024 where expert faculty will share new insights on practical strategies to support the management of #EpidermolysisBullosa (EB). Learn more about the 5th EB Clinet Conference here: https://lnkd.in/e9JjJYVz #RareDiseases #ChiesiGlobalRareDiseases
🎉 Thrilled to share that our paper has been published in RSC Advances! This research explores the pathogenesis and treatment of cystinuria, highlighting that the current gold standard treatment is effective in the short-term not through the commonly assumed method, but rather through an alternative mechanism. This work may help to guide new therapeutic strategies... Many thanks to my co-author and supervisor Dr Oisín Kavanagh! DOI: 10.1039/D4RA04469J https://lnkd.in/eKvd4T2b
